Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interleukin-10 and coronary disease].

Ruth Pérez Fernández1, Juan Carlos Kaski

  • 1Coronary Artery Disease Research Unit, Cardiological Sciences, St. George's Hospital Medical School, London, United Kingdom.

Revista Espanola De Cardiologia
|July 13, 2002
PubMed
Summary

Inflammation drives atherosclerosis. The anti-inflammatory cytokine interleukin-10 (IL-10) shows potential protective effects against atherosclerosis development and plaque instability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy.

The pharmacogenomics journal·2026
Same author

Cardiovascular pharmacotherapy in 2025.

European heart journal. Cardiovascular pharmacotherapy·2026
Same author

Great debate: preventive percutaneous coronary intervention added to optimal medical treatment should be the default treatment for non-flow-limiting vulnerable plaques.

European heart journal·2026
Same author

Exercise treadmill testing for efficacy evaluation in randomized, controlled trials.

American heart journal·2026
Same author

Optimizing cardiovascular pharmacotherapy in older adults with frailty.

Nature reviews. Cardiology·2026
Same author

Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy.

European journal of heart failure·2025

Area of Science:

  • Cardiovascular Science
  • Immunology
  • Inflammation Research

Background:

  • Atherosclerosis pathophysiology is increasingly understood as an inflammatory process.
  • Inflammatory cells and pro-inflammatory cytokines are abundant in atherosclerotic lesions.
  • These inflammatory mediators influence clinical presentation, disease progression, and plaque stability.

Purpose of the Study:

  • To investigate the role of anti-inflammatory cytokines, specifically interleukin-10 (IL-10), in atherosclerosis.
  • To explore the potential protective effects of IL-10 in the context of chronic inflammation and cardiovascular events.

Main Methods:

  • Review of current understanding of inflammatory mechanisms in atherosclerosis.
  • Examination of studies demonstrating IL-10 expression in human atherosclerotic plaques.
  • Analysis of animal experiments investigating the impact of IL-10 levels on lesion development.

Main Results:

  • IL-10, an anti-inflammatory cytokine produced by T-lymphocytes and macrophages, exhibits anti-inflammatory effects.
  • IL-10 expression has been confirmed within human atherosclerotic plaques.
  • Animal studies indicate that low IL-10 levels correlate with extensive and unstable atherosclerotic lesions.

Conclusions:

  • Evidence suggests a potential protective role for IL-10 in mitigating atherosclerosis.
  • Viewing coronary disease as a chronic inflammatory condition opens new therapeutic strategies.
  • Further research into IL-10's role may lead to novel management approaches for ischemic heart disease.

Related Experiment Videos